PHASE II TRIAL ASSESS SFTY OF IMNOSPRSN W/DRAWAL IN LIVER TRNSPLNT RECIP W/HEP C

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项前瞻性的多中心、开放标签、随机试验，丙型肝炎相关性肝衰竭的参与者接受肝移植，并接受他克莫司和皮质类固醇的免疫抑制诱导。移植后3个月内皮质类固醇逐渐减少，他克莫司仍在继续。参与者定期接受肝炎复发和同种异体移植排斥反应的评估。移植一年后，适合停药的参与者被随机分配到免疫抑制停药组或维持组。被分配到停药的参与者在一年内接受预定的缩减。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective multicenter, open-label, randomized trial in which participants with hepatitis C-related liver failure undergo liver transplantation and receive immunosuppression induction with tacrolimus and corticosteroids. Corticosteroids are tapered in the 3 months after transplantation and tacrolimus is continued. Participants are regularly assessed for recurrence of hepatitis and for evidence of allograft rejection. One year after transplantation, participants suitable for withdrawal are randomly assigned to immunosuppression withdrawal or maintenance. Participants assigned to withdrawal undergo a scheduled taper over 1 year.